New Oral Anticoagulants and Other Updates. Tracy Minichiello, M.D. Associate Professor of Medicine Chief, SF VA Anticoagulation & Thrombosis Service

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "New Oral Anticoagulants and Other Updates. Tracy Minichiello, M.D. Associate Professor of Medicine Chief, SF VA Anticoagulation & Thrombosis Service"

Transcription

1 Nw O Agu Oh U Ty Mh, M.D. A P M Ch, SF VA Agu & Thmb Sv I hv Du

2 C 65 y m wh HTN u u xm b AFIB. H m u ASA, m, ACE. H h m u. Wh gm w yu ugg k v? 1. ASA 2. ASA u g 3. W 4. Dbg 5. Rvxb NEW CHEST GUIDELINES AFIB CHADS2=0 hy (2B); CHADS 1 gu (1B); uub AC u +g h h (1B)

3 Nw O Agu W N qu mg My ug I wh h Rqum y Fuug INR h m Nw Ag N b g qu Fw ug Avy vm k ug M b Nw O Agu A, J. Hmgy Cygh 2010 Am Sy Hmgy. Cygh my y.

4 Nw O Agu Dbg Rvxb Axb (Px) (X) (Equ) Av Nvvu Nvvu 2012? u AFIB AFIB/DVT v MOA DTI X X R mbm 80% 30-60% 25% Nw O Ahmb Dbg Rvxb Axb (Px) (X) (/) T1/2 hu CYP3A4* -- Y Y GP Y Y -- A N N mg ECT, TT, PTT PT A X

5 RE-LY- DABIGATRAN v WARFARIN FOR STROKE PREVENTION IN AFIB Cy SJ. NEJM 2009 Oum Sk/SEE (1 E) Mj bg G bg I bg DABI 150 % y RE-LY Ru WARF % y RR (95% CI) * ( ) ( ) * ( ) * ( ) My (MI) ( ) *Sy g NNT NNH NNT=172 N/A NNH=204 NNT=227 N/A

6 ANALYSIS OF RELY TRIAL-TTR TTR <57% TTR 57-65% TTR 65-72% TTR >72% W, L 2010 Dbg :Dug I A ub - gy Iu my bg v (m), S Jh w AVOID Ihb u hy bg (m,,kz, qu) USE CAUTION / kz & CC u 75 mg w y

7 Rg C. 505 v 20% hm CVA g 80 Nw FDA Cmmu

8 MI/ACS wh Dbg RR 33% AR 0.27% Uh, K.. Ah I M 2012 Cygh my y. ROCKET AF- Rvxb v W AFIB 20mg QD N I w Mj bg m k & b k GI b CHADS TTR 55% N TTR y CVA wh bk w P MR. N Eg J M 2011

9 P S-Cu Dbg Hy GI bg-u u Ag > 80 Cm hy wh P-g hb A k u Pbm wh BID g Rvxb Hy GI bg-u u Cm hy wh P-g hb/cyp3a4 hb A k u C Yu yu wh w AFIB bg vxb bu h w b ub g INR w guy u h wk/v hu.

10 Sg Dbg/Rvxb B b-cbc, C, PTT/PT, LFTS P u-m gu Mg Ah Av -GI Bg/Sk +/-Lb Fw u 2 wk 1 mh 3 mh *u mhy hk Dbg :Pbg I I k v vvu AFIB 150 mg w y; 75 mg w y CC m/m CCL< 50 m/m. N mm CC< 15m/m Cu b bk hw Wh vg m w hy, u w bg wh h INR bw 2.0

11 Rvxb-Pbg I D 20 mg m CC> 50 m/m D 15 mg m CC 15-50m/m (bw CYP 34-, m vm, ) Wh m w vxb wh INR 3.0 Wh m vxb w g vxb, g g w gh C Whh g bg ) 66 y w/ AFIB, ESRD, y INR m wh TIA b) 66 yu wh AFIB & MVR ) 83 y 50 kg wm wh CRI (C C 30 m/m) wh w AFIB ) h bv

12 ARISTOTLE Axb vu W P wh A Fb Chh B. Gg, M.D., Jh H. Ax, M.D., M.H.S., Jh J.V. MMuy, M.D., R D. L, M.D., Ph.D., E M. Hyk, M.D., M.P.H., Mh H, M.D., Hu R. A-Kh, Ph.D., Jk A, M.D., D A, M.D., Av Avzum, M.D., Ph.D., M. C Bh, M.D., R Dz, M.D., J. D E, M.D., Ju A. Ezkwz, M.B., B.Ch., Gg Fk, M.D., Dv G, M.D., Mg G, Ph.D., B J. Gh, M.D., Sgy Gy, M.D., Ph.D., Shy G, M.D., A G. Hm, M.D., S H. Hh, M.D., Jh Hwz, M.D., Pu Mh, M.D., Ph.D., P Jky, M.D., B S. Lw, M.D., J Lu Lz-S, M.D., Pm P, M.D., Ax Pkhmk, M.D., Fk W.A. Vhug, M.D., Ph.D., Ju Zhu, M.D., L W, M.D., Ph.D., h ARISTOTLE Cmm Ivg Gg CB, N Eg J M Smb 15, 2011 ARISTOTLE: APIXABAN V WARFARIN AFIB k 21% 5mg BID 20% CVA mj b 13% h 11%* Gg CB. N Eg J M 2011.

13 Th Th W Th Nw Cm v W- Sk k DABIGATRAN RIVAROXABAN APIXABAN X X INTRACRANIAL BLEED X X X MORTALITY X X X** BLEEDING GI bg GI bg y u DRUG INTERACTIONS L-GP G & CYP3A4 CYP 3A4 NUISANCE S 10-20% y DOSING BID QD BID METABOLISM 80% RENAL 60% RENAL 25% RENAL AFIB TREATMENT COST y mh u w < 20 $80* $960 bg $ $260 ~$3000 vxb $8.00 $260 ~$3000

14 Au VTE Tm T Nm Dug Y Pubh Ov wh h/lmwh HR: Ru VTE v. w (95% CI) HR: Mj Bg v. w (95% CI) RE COVER (DVT / PE) b 2009 Y 1.10 ( ) 0.82 ( ) RE COVER II b ONGOING EINSTEIN DVT v 2010 N 0.68 ( ) 0.65 ( ) EINSTEIN PE v 2012 N 1.12 ( ) 0.49 ( ) Shum S NEJM 2009; E Ivg NEJM 2010 & NEJM 2012 EINSTEIN-Rvx Symm DVT V 2.1% vx 3% w Th EINSTEIN Ivg. N Eg J M 2010;363: V 1.3% vx 7.1% b DVTby 82% M b 5.4% v 1.2% Cy SJ NEJM 2011

15 Ky D Dbg D hmb hb Tk w y 5 y (.g. LMWH) m Rvxb D FX hb Tk w y 3 wk, h y C b u mhy

16 C Yu bg m yu h h hvg hymy u h u hy x wk. H w kw wh h hu h bg. R Fu Dbg-Pv Mgm 1/2 Pu wh k bg (m--m u gu ugy) Pu wh hgh* k bg ( mm u gu ugy) P- CC >50 m/m CC m/m S bg 1 y b u (Tk 2 y b u) S bg 2 y b u (Tk 3 y b u) S bg 2 4 y b u (Tk 3 5 y b u) S bg 3 4 y b u (Tk 4 5 y b u) P- ( ) / C umg hy h g vy wh hm h b hv, g bg k u h hmbmb k V Ry Thmb Hm 2010; Duk Cu Phm Dg 2010

17 P- P R Fu Nm m mm (CC >50 m/m) M mm (CC m/m) Rvxb Pv Mgm H- L (hu ) y Ay u qug u gu S vxb 1 y b u (Tk 2 y b u) S vxb 2 y b u (Tk 3 y b u) ( ) / C umg hy h g vy wh hm h b hv, g bg k u h hmbmb k C A 65 y m wh hy HTN hym m wh w PE. H ASA. H LMWH bg w.yu A) h w h h w u k bg B) u ASA my hyx

18 Rk Bg Wh Sg, Du, T Thy Wh W, A, Cg P Wh A F w + = 2x w + + g=3x H M. Ah I M D w: 10/21/2012 NEW CHEST GUIDELINES CHEST 2012 F kg w w ugg AVOIDING m hy x wh b ky b g h hm: vv, ACS,, CABG (2C)

19 CASE A 55 y m wh PMHx w g wh PE 3 mh g, wh LMWH w. H h h bg m hu. H wk u uvg. C Hw g wu yu mm h y gu? ) 3 mh b) 6 mh ) 12 mh ) y

20 Rk VTE Ru A C VTE Rk 1 y Nx 5 y D DVT 3% (6%) <10% Mj 3% 10% M 5-6% 15% Uvk A 10% 30% Ru > 10% > 30% K, B 2005 Gu Du Agu VTE I 8h ACCP gu 2012 AHA 2010 ASH mm 2008 F VTE y k 3 mh (G 1B). 3 mh (C I Lv A) 3 mh F h (uvk) VTE A 3 mh, g-m m k/b k (G 2B). A 6 mh, (C I Lv A) 6 mh Ru VTE Lg m (G 1B). I C I Lv A). Lg m APLS, AT y u K CHEST u Fb 2012;J Cu 2011; Bumux H Hmgy 2009

21 C kh y u D ( v hmb) Lw k u/pe Pxm- y 5 u k v PE v. DVT P g wh PE 3x m ky u u PE h h g wh DVT Bg T J Thmb Hm Mgm T Ug D-m Ru Dm Du Agu P G. N Eg J M 2006 Duk A I M 2010 Sym Rvw D-m + 8.9% D-m 3.5%

22 C D Ru C Lg w hygm 5-7 m v D-m >250 ug/l AC BMI >30kg/m2 Ag> 65 Fm wh 0-1 k h u k 1.6%: 2 = 14% Rg CMAJ Augu 2008 Im Thmbh Ru Rk P gu Ru VTE Y 2.6% 1 hmbh 2.5% I VTE vk 1.8% I VTE uvk 3.3% Uvk wh hmbh 3.4% Uvk whu hmbh Ch JAMA % Shum Am j M 1998

23 Ivu Bg Rk Agu Bg Rk F Ag > 75 Pvu GI b wh vb u Pvu b w R/h u A hy C A I M 2010 A Pv Ru VTE. Ru VTE ASA 6.6% Pb 11.2 % VTE 40% N mj bg B C. N Eg J M 2012

24 Du Agu Uvk VTE g k C x ( P E, m, h m b h ) D u : C u : < 1 g u u D - m 3 0 y, w k I v R g x R V O C u g u U / S 3 m I b g k h g h A C 3 m h IF DVT G u/ mu -m. I - m u u AC g k C x ( P E, m, h m b h ) D u : C u : < 1 g u u D - m 3 0 y, w k I v R g x R V O C u g u U / S 3 m I b g k h g h A C 3 m h IF DVT G u/ mu -m. I - m u u AC PTS D-m Bm > 30 Ag > 65 C ASA gu

Oxfordshire Fire and Rescue Service

Oxfordshire Fire and Rescue Service Oxfh F Ru Sv F f v bk K Sg Tw Lk KS2 PHSE Czhp 1C, 3A, 3E & 5D NAME: Ffgh U h f u wh h mg! 1 2 3 4 5 6 7 8 9 10 11 12 13 b f g h j k m 14 15 16 17 18 19 20 21 22 23 24 25 26 p q u v w z z 26-19 18-13 4x5

More information

New Oral Anticoagulants

New Oral Anticoagulants New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.

More information

Monitoring Call Center Applications with Application Response

Monitoring Call Center Applications with Application Response Mg App wh App p U Hh App p m mg h pfm f pp, h kp pp by pv b pp h hy f g m. Wh App p, y f pp pmz p m fy bh pfm pbm bf hy mp pvy. App p m h - p m f h pp whh y pv y wh pg m q: h kp pp, m b pp, h. I pv --

More information

Games and activities guide

Games and activities guide Gm d v gud W hv mpd Chg gm d v hd d yug pp h uu gud. C Av Gm Chg wp gm S u ud Fu ugh d Og d m Chg h B gm Lgh d dk Puzz d Quzz Chg quz P d gm Cwd puzz Wd h Rug wy Quz Qu Av P h pp Spg d Av Gm Chg Swp Gm

More information

Child Care Resource Kit celebrate relationships!

Child Care Resource Kit celebrate relationships! K u R C d C b d k f Fu w y Pd by p! u R Cd C g d g b u d yu g p m d fu g f pg m g w Tk yu C g p D Ng kd pg u bk! T y g b fm dy m d md g g p By pvdg ud d ug yu u f D Ng Cg v, yu b pg up g u d g v bf W v

More information

Epidemiology of Adverse Events in Air Medical Transport. Russell D. MacDonald, MD, MPH, Brie Ann Banks, BSc, MD, Merideth Morrison

Epidemiology of Adverse Events in Air Medical Transport. Russell D. MacDonald, MD, MPH, Brie Ann Banks, BSc, MD, Merideth Morrison Egy Av Ev A M T R D. MD, MD, MPH, B A Bk, BS, MD, Mh M A Ojv: Th v y qy - v v gy g y. Mh: R y g y w vw g h w h y v- v- v v. Tw vw y v v gz h g h xy. Dv w v v, wh qy,000 gh,000 h w. R: Bw Jy, 2002, J 30,

More information

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957

More information

Book of Plans. Application for Development Consent. Thames Tideway Tunnel Thames Water Utilities Limited. Application Reference Number: WWO10001

Book of Plans. Application for Development Consent. Thames Tideway Tunnel Thames Water Utilities Limited. Application Reference Number: WWO10001 h w u h U Appc f vp Appc fc ub: B f c f:. Bc Swg AF gu : gu ()(), () H cp vb Bx F Ju h pg f b Appc f vp : B f f Vu Bx Vu Sc c wg p c jc-w wg p c jc-w wg cqu p jc-w wg p 4 jc-w wg w pc cg p S wg Ac S S

More information

Towards A Holistic Analysis of Mobile Payments: A Multiple Perspectives Approach

Towards A Holistic Analysis of Mobile Payments: A Multiple Perspectives Approach Tw A H Ay f b Py: A u Pv A J Ou, Yv Pu D f If Sy, HEC S f E, Uvy f Lu, 1015 Lu, Swz Ab A b v vu, y u w b y w b k f b. T v b u f k, yz y y bu ff vv. F u, w u w u y w uv f f b y u y u. T, w y v w f v v by

More information

Knowledge as a Service

Knowledge as a Service Kwdg v Bg dym kwdg y m mx WD, A Xx Cmpy pvd m-h kwdg mgm, m d y hp bd dv m ffv m v xp. WD Kwdg v dp y m h p wh zd, dym d p f kwdg pvd ffv d pp f y m h mx. Why gd m kwdg mp? A gz f g m, mvg mh ff pb w-

More information

A Simple Tale Joseph Conrad

A Simple Tale Joseph Conrad E R L y fm p, M V w q bf b pbk w x- w. I b,b fk. H y b y b m f w mybk w f f y y w x Ipwm.. I w vywy p p ; k w q w p p k p b, y f b m f p, m, f m f f ; p w w w. I y m pm p b w pp f T, ; m, b w vp, p wt

More information

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71 Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.

More information

Missing and Exploited Children

Missing and Exploited Children U.. D f J ff f J P ff f Jv J Dqy Pv F R M Ex h A Dy f Lw Ef h Pb Pv A F Ay Tk F f M Ex h xh E U.. D f J ff f J P 810 vh NW. Wh, D 20531 E H. H, J. U.. Ay G L. Rb A Ay G Jff wkwk A A ff f Jv J Dqy Pv ff

More information

E. OZCEYLAN /International Journal of Lean Thinking Volume 1, Issue 1 (June 2010)

E. OZCEYLAN /International Journal of Lean Thinking Volume 1, Issue 1 (June 2010) I J L T k gv m1 I 1( J 2 0 1 0 ) LT k g. jmg: www. k g.m/ j AD S S m C m T M L g E Öz S ç ku D m I E g g C m 4 2 0 3 1 K T k z @ k.. ABSTRACT KEYWORDS L g m g m T m m m M m k g m m g g. F m T A m m x m

More information

New Oral Anticoagulants and Other Updates. Tracy Minichiello, M.D. Associate Professor of Medicine Chief, SF VA Anticoagulation & Thrombosis Service

New Oral Anticoagulants and Other Updates. Tracy Minichiello, M.D. Associate Professor of Medicine Chief, SF VA Anticoagulation & Thrombosis Service New Oral Anticoagulants and Other Updates Tracy Minichiello, M.D. Associate Professor of Medicine Chief, SF VA Anticoagulation & Thrombosis Service Case 65 yo man with HTN & CHF is found on routine exam

More information

Sticky News. sticky rice cooking school newsletter

Sticky News. sticky rice cooking school newsletter S R C S V A T 3 HS SA 2009 S Nw w #05 m 2010 j v T L & S O I M T Ow C F... S C Nw C C A Smb 2010 M C S R C S BEST FOOD EXPERIENCE 2009 N F C w S R C S w w b Aw T 6 B F Ex A. A N F A Tv Tm Aw, w b M Ex

More information

NEGLIGENT INFLICTION OF EMOTIONAL DISTRESS IS STILL ALIVE IN TEXAS

NEGLIGENT INFLICTION OF EMOTIONAL DISTRESS IS STILL ALIVE IN TEXAS NEGLIGENT INFLICTION OF EMOTIONAL DISTRESS IS STILL ALIVE IN TEXAS (I H Oy B Sy W) By F A. Sp 1 G W. (W) Hz 2 M Tx wy w p v w w Sp C Tx b 1993 By v. K. 3 Hwv, b Tx k k. T y b pp, b vb, y. I Tx p b by jy

More information

Objectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants

Objectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence

More information

Freshwater Fish Communities of Southeastern New Hampshire

Freshwater Fish Communities of Southeastern New Hampshire F F mmu f u mp O WA c J IG G c g A I V m WI I AU Y u g v A WI I AU Up c W W u Wu F g g u F p p m F D f v g m u p Wc F m g g v f p I v u c b A IV A WI I U A c c W WO G A A A W u v A I W I A U m u c c Gu

More information

Why the PRS System is right for you.

Why the PRS System is right for you. Wy PRS Sym y. 2. Hw ym. Fm b w m w b w ym. A w jb b bm w m m y w m. W b mk w w my w w by w b mb. S jb - m w w b w mm. Sm m bm w- q b m. O y y mb m m w w y w. D qky bm b k w y b b k I. L b b 2005 Pm R Sym

More information

Total 34. Exhibit 22 - Page 1

Total 34. Exhibit 22 - Page 1 FCC/EEO Pgm u Rd NY Mk Fu Tm V - 76.172(b)(1) Juy 15, 2012 hugh Juy 14, 2013 FCC U D D Jb T V 11833 NYC Mk D S R (DSR) 1 11833 NYC Mk D S R (DSR) 1 11833 NYC Mk D S R (DSR) 1 11833 NYC Mk Rd S Su 1 11833

More information

english parliament of finland

english parliament of finland gh f fd 2012 P cvd f h f y f h g Mdy, 6 Fby 2012. A h d MP, K T hd h ch h c f h S. E H (Sc Dcc Py) w -cd S, P Rv (N C Py) F Dy S d A Jh (F Py) Scd Dy S. Th g c c Tdy, 7 Fby, whch Pd f h Rbc Tj H d P f

More information

The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.

The speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products. Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives

More information

Compare the clothing in the Renaissance to the clothing now. Look up Renaissance architecture on the Internet and in books.

Compare the clothing in the Renaissance to the clothing now. Look up Renaissance architecture on the Internet and in books. Ld d Vc A Sudy d Pu L f Gd O Th W d Iud by V Tmbch Fc A d Auh f Chd d A Iuc Sk, SK Submd by V Tmbch. Pd wh pm. A Ccp, Sk d Objcv Sud w: L bu h Ld d Vc. L bu h m fmu p h hy f. L h pu g. L h p w pd fm v

More information

Anticoagulation For Atrial Fibrillation

Anticoagulation For Atrial Fibrillation Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator

More information

With content marketing, you can move beyond measuring success in terms of impressions, awareness, or perception.

With content marketing, you can move beyond measuring success in terms of impressions, awareness, or perception. L k m k?j SHSMD y! A m k b mm y SHSMD b y k w y y m. Byj 4 000 mm y SHSMDm mb y w x b y y j bm y : F w b m y x A w m m w b b T w m Am H A R b w S b B b m k A m m m! V www. m. /b. Sy H Sy Mk Dm P Mk P V

More information

ADVANCED VIDEO EDITING WITH MPEG VIDEO WIZARD.

ADVANCED VIDEO EDITING WITH MPEG VIDEO WIZARD. S pm ADVANCED VIDEO EDITING WITH MPEG VIDEO WIZARD TO EDIT OUT COMMERCIALS: C F b Op Bw yu w F pup u I w b pm m m D TV Jy C A umb w pp pj ww T, Ipu ww U yb wy S p b yu p w yu w m p Yu u w y mv wy m T up

More information

New Oral Anticoagulants. July 2012

New Oral Anticoagulants. July 2012 New Oral Anticoagulants July 2012 Objectives Review coagulation cascade and previous treatment options for anticoagulation Understand points of interaction within coagulation cascade and new oral agents

More information

Disclosures. New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century

Disclosures. New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University

More information

The author has no disclosures

The author has no disclosures Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author

More information

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,

More information

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations

Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant

More information

CBOE Research Circular #RS DATE: November 2, 2005 TO: Members RE: New Listings

CBOE Research Circular #RS DATE: November 2, 2005 TO: Members RE: New Listings CBOE Research Circular #RS05-775 DATE: November 2, 2005 TO: Members RE: New Listings Arena Pharmaceuticals, Inc. (ARNA) Cabot Oil & Gas Corp. (COG) Centene Corp. (CNC) Active Date - 11/3/2005 Active Date

More information

Your Touchstone Energy Cooperative. Mountrail-Williams Electric Cooperative

Your Touchstone Energy Cooperative. Mountrail-Williams Electric Cooperative NOVEMBER 2015 Y T Egy Cv Y T Egy Cv Y T Egy Cv Y T Egy Cv M-Wm E Cv Y T Egy Cv Y T Egy Cv WHITE WHITE WILLISTON 577-3765 STANLEY 628-2242 NEW TOWN 627-3550 Hy y! Hy Tkgvg fm M-Wm E Cv b ff.m.m MOUNTRAIL-WILLIAMS

More information

IMPROVING PRODUCTIVITY OF MANUFACTURING DIVISION USING LEAN CONCEPTS AND DEVELOPMENT OF MATERIAL GRAVITY FEEDER A CASE STUDY

IMPROVING PRODUCTIVITY OF MANUFACTURING DIVISION USING LEAN CONCEPTS AND DEVELOPMENT OF MATERIAL GRAVITY FEEDER A CASE STUDY T m3 D T g jmpg: www. g.m/ j MPONG PODUCTTY OF MNUFCTUNG DON UNG N CONCPT ND DOPMNT OF MT GTY FD C TUDY K.Hmd Dpm M gg PG Cg TgyC 64 4 d. D.mv Dpm M gg PG Cg TgyC 64 4 d..cd j* G.dj Dpm M gg PG Cg TgyC

More information

Manual for Vegetable Production in Botswana

Manual for Vegetable Production in Botswana OF RESEARCH M V P Bw H R Pm V: W w w W Dm A R mm v x v vm v mv w M: W w x O m v vv w m mz v : Ev z Cv G mm W w v m mw v mv w vm V: W w v Cm Cm W w m mvm v v S O v q v w mm v m w w mv j m m Sv W x v m v

More information

Working Paper Series Department of Economics Alfred Lerner College of Business & Economics University of Delaware

Working Paper Series Department of Economics Alfred Lerner College of Business & Economics University of Delaware Wk p Dp f Af L C f B & Uv f Dw Wk p N. 2005-21 Rf H : Mv B T Jff M 1 I. I vv, Ab - G, R Bv, H, f Cbv H ;. I f b v K Kf M. T. K w f f w-fv Uv f Dw. W wk v pj, pp p wk pj B. K w f f pp f b. H f Uv Fb fwp

More information

English Language Program

English Language Program Egh Lgug Pgm Wm Mu Ry Uvy Fu-m Egh Lgug Pgm Ou V: Cg xp g xp f wd f pb Th fu fu-m pgm Mu Ry Uvy: Egh Fud (EF), Egh f Adm Pup (EAP), Egh f Advd Cmmu (EAC) d Thg Egh Fg Lgug (TEFL) Mu Ry w bhd 191 d dy h

More information

The. Great British. Lunch Revival. Recipe Book. brought to y H CH EES E IT IS % BR

The. Great British. Lunch Revival. Recipe Book. brought to y H CH EES E IT IS % BR G B Lu Rvvl R B u by bug y H CH EES E H CH EES E ud b 100% B, w wd wg d lly f dlv flvu, v d fm. W g f dlu fm mld mu, lud, bl, ld, gd d v 30% l f, u vy qum! W ud v wd w M Mll, w f Bugudy & Bl fé, F By,

More information

Neighborhood Evaluation in Acquiring Stock Trading Strategy Using Genetic Algorithms

Neighborhood Evaluation in Acquiring Stock Trading Strategy Using Genetic Algorithms Il Jul Cpu I S Iul M Appl. ISSN 215-7988 Vlu 4 (212) pp. 366 373 MIR Lb, www.lb./j/x.hl Nhbh Elu Aqu Sk S U G Alh Kzuh Mu Hu S p Cpu S, Cll E, Nh U, 1 Nkw, ku, u-h, K, 963-8642, Jp u@..h-u..jp Ab: W pp

More information

Earthquake Hazard Zones: The relative risk of damage to Canadian buildings

Earthquake Hazard Zones: The relative risk of damage to Canadian buildings Earthquake Hazard Zones: The relative risk of damage to Canadian buildings by Paul Kovacs Executive Director, Institute for Catastrophic Loss Reduction Adjunct Research Professor, Economics, Univ. of Western

More information

Special Advertising Section

Special Advertising Section S Ad S Nw Yk H F S B R, f d -kd f kwd wkf, h G Rh, Nw Yk R d k d b. By S H. B Th d f h -y G Rh, Nw Yk R f: 18 d d, xy j k, f h w hh- d 7% f h wd y f fh w. By y, h wh h d f b. Y h f y f, y d b k d h I Dy

More information

Novel OAC s : How should we use them?

Novel OAC s : How should we use them? Novel OAC s : How should we use them? Jean C. Grégoire MD, FRCP(c), FACC, FACP Associate Professor, Université de Montréal, IntervenJonal Cardiologist, InsJtut de cardiologie de Montréal Disclosures Speaker

More information

u if 24 nypost.com/pagesixmag

u if 24 nypost.com/pagesixmag C M Y f C 24./gxg PSM_PAZ. 1 8/29/11 3:22:47 PM P z D L H k E H b f B T S.? b b + J b T b g P!! E P g b S! b A S 1 Ev, Pz k fg b. O, f M, g. S f S N M, f Mb. I, N B, g. T, g C, g Nvb 1../gxg 25 PSM_PAZ.

More information

Community. Collaboration. Careers.

Community. Collaboration. Careers. Cy. Cb. C. I h My S Ey Ph f P P 2 Tb f C I h My S Ey Ph...4 Cg T My S C Ey...6 Hw MSEP wk f y...6 Ph... 7 Hw MSEP wk f... 7 Why H My S?...8 B C...8 Cy-b v...8 P-b v...9 Th MSEP P Bf...10 Th v f bg MSEP...

More information

A -4 4-- ~A--~--44-~--~- -~

A -4 4-- ~A--~--44-~--~- -~ 2 A A Tb Ty f c Rc Acvy mu Su g Pc Cy Cvcu ffc M Pyc c Iffc vm muu Ry Dm uv Fg Cvcu ffc Pb gw m Mu mu c cvy S g Dm uv Pb gw m S g Ib uc m S M Pb y Dy Dy Huc Hy cvy* mu2 D K Sgm *O uby x uc k k2 k3 Ec c

More information

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012 New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk

More information

DevOps & WebSphere: Experiences in Chef enabling the IBM WebSphere Liberty Profile

DevOps & WebSphere: Experiences in Chef enabling the IBM WebSphere Liberty Profile Jm h WbSh S d dm 5 h h 4 DO & WbSh: Ex Chf b h IB WbSh Lb f 4 IB C 4 IB C L Dm IB C 4 Rh Rd h fm d h b dd f fm Wh ff w md f h m d f h fm d h b, dd S IS wh w f kd, x md I dd, h fm bd IB d d, whh b h b IB

More information

OWNER S & INSTAION MANUAL

OWNER S & INSTAION MANUAL OWNER S & INSTAION MANUAL SYSCONTROL CWC 03 Cz C P k f y. R f fy bf g q. Ab : SYSCONTROL CWC 03 HP SYSCONTROL CWC 03 HR Tk y vy f g. T 2-G Cz C T f b f g z f. CONTEN T P AGE I.I L f fg...2 N...3 I...3

More information

Drug Hypersensitivity Reactions: Pathomechanism and Clinical Symptoms

Drug Hypersensitivity Reactions: Pathomechanism and Clinical Symptoms D yvy R: P Sy W J P, MD,, *, Jq A, MS, B D, MS, T G, MS, Mk K, PD, D Yy, PD KEYWRDS P G S IE Ty IV Ex M yvy F T y v, w v y y w v y P x y, y (w, y vy S,, v y vy T w y v wy y w, yy q, w D v y A y B : Ty

More information

Production Supervision Incorporated With Network Technology-A Solution For Controlling In-Process Inventory

Production Supervision Incorporated With Network Technology-A Solution For Controlling In-Process Inventory T m4 2 T g mpg: www. g.cm/ Pc pv cp W Nw Tcgy-A F Cg -Pc vy v* DEPARTMENT Egg FM NDA PVT TD Amb E-m:y9@gm.cm ABTRACT cx mcg mgm mm c pc w--pc WP mgm pc vy c vb pc pc bcm v pc p. D gwg pc qm p cmc b mcg

More information

Anticoagulants. Denver Health April 12, 2011

Anticoagulants. Denver Health April 12, 2011 New Oral Anticoagulants Rebecca Hanratty, MD Denver Health April 12, 2011 Overview Why we need alternatives to warfarin Review of the 3 new oral anticoagulants Results from major trials: Thromboprophylaxis

More information

Cell Structure and Function

Cell Structure and Function Nm C D Chp 7 C Suu d Fu S 7 1 Lf I Cu (pg 169 172) Th xp wh h hy. I db h h f w g f, pky d uky. Idu (pg 169) 1. Wh h uu h mk up vy vg hg? Th Th C Thy (pg 169 170) 2. Wh w A v Luwhk h f h 1600? H w h f p

More information

Goals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD

Goals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs

More information

Masters Mens Physique 45+

Masters Mens Physique 45+ C G x By, F, hysq, Bk Chpshps Ap, Cv Cy, Cf Mss Ms hysq + Fs Ls Css Ov Css s G MC Chpk M+ W M+/MC y Bs 9 8 9 9 8 B O'H 8 9 8 S Rs 8 8 9 h K 9 D Szwsk 8 9 8 9 9 G M+ h D Ly Iz M+ 8 M R : : C G x By, F,

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin. To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation

More information

Complex cultural and ecotourism development of Diósgyőr Lillafüred

Complex cultural and ecotourism development of Diósgyőr Lillafüred Dg Lfü Cmpx m pm f Dg Lfü NHOP-211/A-09-2F-2011-0002 Pj h: p f, w wh gh F f h pj: gb pm : 2 714 459 160 HUF q: 2 272 384 272 HUF C f Dg Jg Hgg g f Lfü R p f h pm: 11 J 2012 30 J 2015 h pj w wh wh -fg fm

More information

Geotechnical engineering education and practice in Croatia

Geotechnical engineering education and practice in Croatia Gh du d p C V Szv-N d M S Kvv Fu f Cv E, Uv f Zb, Zb, C ABSTRACT: Th N p Gh du d p C pd A h vvw udd Th ph h h h ud h hh du d h B p Gh u ffd fu C Uv d Ph d bh h d d h w uu I hw h h du h d C, d ud u du f

More information

BERGEN COMMUNITY COLLEGE DIVISION OF BUSINESS, PERFORMING ARTS AND SOCIAL SCIENCES BUSINESS DEPARTMENT

BERGEN COMMUNITY COLLEGE DIVISION OF BUSINESS, PERFORMING ARTS AND SOCIAL SCIENCES BUSINESS DEPARTMENT BERGEN COMMUNITY COLLEGE DIVISION OF BUSINESS, PERFORMING ARTS AND SOCIAL SCIENCES BUSINESS DEPARTMENT BUS 207 Pcpl f Mg S, Y Syllbu Dl Cu Nub/Sc: Mg Dy & T: Iuc: Offc Lc: Ph: R Nub: Offc Hu: E-l : C u

More information

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix

More information

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012 The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era CCRN State of the Heart 2012 June 2, 2012 Disclosures I have I have been involved in trials of new anticoagulants and have received

More information

Catalogue 4. Arctic Arctique. Nautical Charts and Publications Cartes et publications nautiques

Catalogue 4. Arctic Arctique. Nautical Charts and Publications Cartes et publications nautiques Hphc vc vc hph c h Pbc pbc cc c www.ch.c.c www.c.c.c 3 H ÉP Wh p 3-3- H / -Q m m p & h --3 P m -9-9 c.. f m -3- hch H P mp --3 W W / V W c Hb h Ww -- pp Hb -9-9 c vc w wc -3- Wm -- Hm Hw -- P / mch Whb

More information

english parliament of finland

english parliament of finland gh f fd 213 P cvd f h f y f h g 4 Fby 213. E H (Sc Dcc Py) w -cd S, P Rv (N C Py) F Dy S d A Jh (Th F Py) Scd Dy S. Th g c c 5 Fby, wh Pd f h Rbc S Nö d P f h f fwg h c 212. P g dc c 12 Fby h b f P M c.

More information

New Oral AntiCoagulants (NOAC) in 2015

New Oral AntiCoagulants (NOAC) in 2015 New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research

More information

ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν

ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ. Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν ΠΟΙΟ ΑΝΤΙΠΗΚΤΙΚΟ ΓΙΑ ΤΟΝ ΑΣΘΕΝΗ ΜΟΥ? ΚΛΙΝΙΚΑ ΠΑΡΑΔΕΙΓΜΑΤΑ Σωκράτης Παστρωμάς Καρδιολόγος Νοσοκομείο Ερρίκος Ντυνάν The AF epidemic Mayo Clinic data (assuming a continued increase in the AF incidence) Mayo

More information

Garment Manufacturing Through Lean Initiative-An Empirical Study On WIP Fluctuation In T-Shirt Production Unit

Garment Manufacturing Through Lean Initiative-An Empirical Study On WIP Fluctuation In T-Shirt Production Unit m D g jmpg: www. g.m/ j Gm Mg g v- mp dy O WP F - Pd U B. Km * Cpdg :.p Gdgm Uvy Gdgmd..b98@gm.m D. V.. mp Cpd: Pp Nd Cg ggdd BC KYWOD D g mg Gm pd g v pd mx d Gb M. pp w Cmzd mpm mmzg p w W pg WP g m

More information

Time of Offset of Action The Trial

Time of Offset of Action The Trial New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About

More information

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia

More information

Xarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason

Xarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical

More information

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will

More information

Transient Voltage Suppressor SMBJ5.0 - SMBJ440CA

Transient Voltage Suppressor SMBJ5.0 - SMBJ440CA Features: Glass passivated junction Low incremental surge resistance, excellent clamping capability 600W peak pulse power capability with a 10/1,000μs waveform, repetition rate (duty cycle): 0.01% Very

More information

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7

More information

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015 Financial Disclosure Information Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management Robert D. McBane, M.D. Division of Cardiology Mayo Clinic Rochester Dual Antiplatelet

More information

Current and new oral Anti-coagulation. Lancashire and Cumbria Network 2 February 2012

Current and new oral Anti-coagulation. Lancashire and Cumbria Network 2 February 2012 Current and new oral Anti-coagulation Lancashire and Cumbria Network 2 February 2012 Question Warfarin is an abbreviation What does the W stand for? What is this plant and what is the connection with warfarin?

More information

What s New in Stroke?

What s New in Stroke? 5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario

More information

Anticoagulation Therapy Update

Anticoagulation Therapy Update Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2

More information

Direct Oral Anticoagulants (DOACs) Who Gets What?

Direct Oral Anticoagulants (DOACs) Who Gets What? Direct Oral Anticoagulants (DOACs) Who Gets What? Kathryn Hassell, MD Professor of Medicine, Division of Hematology University of Colorado Denver Disclosures No financial or commercial conflicts of interest

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

B y R us se ll E ri c Wr ig ht, DV M. M as te r of S ci en ce I n V et er in ar y Me di ca l Sc ie nc es. A pp ro ve d:

B y R us se ll E ri c Wr ig ht, DV M. M as te r of S ci en ce I n V et er in ar y Me di ca l Sc ie nc es. A pp ro ve d: E ff ec ts o f El ec tr ic al ly -S ti mu la te d Si lv er -C oa te d Im pl an ts a nd B ac te ri al C on ta mi na ti on i n a Ca ni ne R ad iu s Fr ac tu re G ap M od el B y R us se ll E ri c Wr ig ht,

More information

ARTICLE IN PRESS. International Journal of Lean Thinking Volume 1, Issue 1 (June 2010)

ARTICLE IN PRESS. International Journal of Lean Thinking Volume 1, Issue 1 (June 2010) ART CLE N PRESS J L T k V m ( J 2 ) LT k jm: www k m/ j AF S M A Ow / M D mm F m C m M A A R C OGL U S ç ku D m E C m 4 2 3 K T k m @ m m ABSTRACT KEYWORDS F m m m m K m m m w w Ow/ m j m O m j m m m ARTCLE

More information

Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain

Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Review of Non-VKA Oral AntiCoagulants (NOACs) and their use in Great Britain Dr Alexander (Ander) Cohen Guy s and St Thomas Hospitals, King s College London, UK Pavia Spring Meeting 13 June 2014 Overview

More information

Future Trends in Airline Pricing, Yield. March 13, 2013

Future Trends in Airline Pricing, Yield. March 13, 2013 Future Trends in Airline Pricing, Yield Management, &AncillaryFees March 13, 2013 THE OPPORTUNITY IS NOW FOR CORPORATE TRAVEL MANAGEMENT BUT FIRST: YOU HAVE TO KNOCK DOWN BARRIERS! but it won t hurt much!

More information

4-H 500 OHIO STATE UNIVERSITY EXTENSION. Science Fun with PHYSICS. Name: Age (as of January 1 of the current year): Club name: Advisor name: County: _

4-H 500 OHIO STATE UNIVERSITY EXTENSION. Science Fun with PHYSICS. Name: Age (as of January 1 of the current year): Club name: Advisor name: County: _ OHIO STATE UNIVERSITY EXTENSION 4-H 500 S F PHYSICS Nm: A ( f Jy 1 f y): Clb m: Av m: Cy: _ A Ky Blkf, Ex E, 4-H Cy D, T O S Uvy, Al Cy Sy S. C, fl Ozl Av f Gl Exl 4-H Clb, W, O Rv Ml F, PD, R L, Bll Rb

More information

List of Part Numbers Manufacturer's No. / Hella No.

List of Part Numbers Manufacturer's No. / Hella No. List of Part Numbers Manufacturer's No. / No. List of part numbers.02-.09 Manufacturer's no. / no..-.53 Note: The original numbers listed in the manufacturer number - number comparison serve exclusively

More information

RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75

RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75 ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin

More information

Vom Prototyp zum MVP. Peter Spisak Senior Lead Architect Online and VAS Development. Public Nicht vertraulich

Vom Prototyp zum MVP. Peter Spisak Senior Lead Architect Online and VAS Development. Public Nicht vertraulich V Py z VP P Sk S Achc O VAS Dv Pbc Nch vch Py DSCOVER, DSRUPT, DEVER Pbc Nch vch x C DSCOVER, DSRUPT, DEVER 3 Pbc Nch vch DSCOVER, DSRUPT, DEVER 4 C - Dvb C C Pbc Nch vch DSCOVER, DSRUPT, DEVER 5 Dcb wh

More information

CALIFORNIA S TRADE PUBLICATION FOR THE HOME LOAN ORIGINATOR

CALIFORNIA S TRADE PUBLICATION FOR THE HOME LOAN ORIGINATOR CORN TRD PUBCTON OR TH HOM ON ORGNTOR OUTTNDNG COMPNY O TH MONTH YOUR PRMR R TT MORTGG NDR m gg mm 9 % g % H B T m gg v m w O f f H R DWOR K! % mm w NO DM N J B C R w g wb b w v B H / P BB B B C T v f

More information

Two River Views. A New Website at a New Home. Two River Community Bank Newsletter Fall 2015

Two River Views. A New Website at a New Home. Two River Community Bank Newsletter Fall 2015 T Rv V T Rv mm Bk Nl Fll 2015 A N W N Hm. W l x mg l l. Dg, l lk m v vg, k ll v l ll kg. Pl, mz ml v, mll z, g mll l. Skg, l. W v l l -vl g l v, g kg m m --g. I, ll l mvg m TRv.Bk. Ol -v gz lgl.k, g l

More information

Auburn University Style Guide & Identification Standards Manual

Auburn University Style Guide & Identification Standards Manual y E k H PM 28 C 9 C MY M y K v B 10 k 0% : 60 64 % % x 11 C M MY Y K v 6 97 1% : % P PM 17 C 2 M MY Y K v 6 88 6% : % P PM 15 8 PM 17 2 B R G ID E & PM ID P E 15 8 T IC IF T IO PM 17 2 D T R D M L 0 0

More information

Novel OACs: How should we use them?"

Novel OACs: How should we use them? Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal

More information

Carrier Locator: Interstate Service Providers

Carrier Locator: Interstate Service Providers : Nmb 1997 Jm K R mm B F mm mm W, 20554 b f f mm B' b Rf Rm, 2000 M, N.W. W, Rm 575. m b b,. (202) 857-3800. b [f m -97.Z] fm F- k ://.f./b/ W W Wb. b fm F- k m b b m (202) 418-0241. : 1 b 1: Nmb f F 1997

More information

1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF

1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology

More information

New Anticoagulants: What to Use What to Avoid

New Anticoagulants: What to Use What to Avoid New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA

More information

Cardiac Sources of Stroke. Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology

Cardiac Sources of Stroke. Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology Cardiac Sources of Stroke Robert N. Piana, M.D. Professor of Medicine Director, Adult Congenital Interventional Cardiology Stroke Pathophysiology Cardiologists Well Suited to Help 795K CVA per year, 87%

More information

PROVIDER APPLICATION FOR MEDICAL LIEN PORTFOLIO PURCHASE

PROVIDER APPLICATION FOR MEDICAL LIEN PORTFOLIO PURCHASE G CA HNOW F OYOUM D CA N C F d g f d gp fm d ( OP ) g p y w U W b p d gf g f p f f 10y W yb q dbyp b mp y d b p b Y dw gf y d k f py m by gy m d f d g p yf mp Wp d d w p ya p f f mub dm d p d W pf p z

More information

2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.

2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2. Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order

More information

Safety Data Sheet TSP - TRISODIUM PHOSPHATE

Safety Data Sheet TSP - TRISODIUM PHOSPHATE Sf D Sh TSP - TRISODIUM PHOSPHATE D f Rv: 2/11/2015 S 1 Ch Pdu d C Idf Pdu/Ch N: Tdu Phh ddhd Ch Fu: N3PO4*12H2O CAS Nub: 10101-89-0 Oh Dg: TSP; du hhh; b; du hh; du hh Dv: Pd b bg f hh d d d f ddu hh,

More information

Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation

Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants

More information

Efficacy in Hip Arthroplasty. Efficacy in Knee Arthroplasty. Adverse Effects. Drug Interactions

Efficacy in Hip Arthroplasty. Efficacy in Knee Arthroplasty. Adverse Effects. Drug Interactions Objectives Just for the RECORD: Rivaroxaban joins the US Anticoagulation Arsenal Anne P. Spencer, PharmD, FCCP, BCPS (AQ Cardiology) Cardiovascular Care Pharmacy Specialist Roper Saint Francis Healthcare

More information